Filing Details
- Accession Number:
- 0000899243-20-019846
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-21 19:19:24
- Reporting Period:
- 2020-07-20
- Accepted Time:
- 2020-07-21 19:19:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1812364 | Relay Therapeutics Inc. | RLAY | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1816130 | Mark Murcko | C/O Relay Therapeutics, Inc. 399 Binney Street, 2Nd Floor Cambridge MA 02139 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-07-20 | 281,617 | $0.00 | 718,123 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-07-20 | 278,829 | $0.00 | 996,952 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-07-20 | 25,000 | $20.00 | 1,021,952 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2020-07-20 | 1,000,000 | $0.00 | 281,617 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2020-07-20 | 990,099 | $0.00 | 278,829 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.
- Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.
- On July 20, 2020, the reporting person purchased 25,000 shares of Common Stock of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering.
Billionaire Hedge Funds
